cleveland clinic glp-1 study shows promise for weight loss, but can you believe the hype? Cleveland Clinic Study Shows Greater

Neural Regeneration Research , 17(3), 482

Alexandra Sowa, M.D., a New York City-based physician double-board certified in internal medicine and obesity medicine, and the author of The Ozempic Revolution

The limited treatment landscape has created significant interest in repurposing existing drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, which address multiple metabolic pathways implicated in fatty liver disease

Incretin-based anti-obesity medications The development of next-generation AOMs, such as incretin-based GLP-1 receptor agonists, offers promising potential for reducing the health impacts of obesity and improving overall public health outcomes

This produces usable energy for training, performance, and daily activity

58(3): 2014 Brooks DE, Mclntosh JE